Manitoba and Saskatchewan Promise to Make Life-Changing Dexcom G6 CGM System Accessible for Children and Young Adults with Type 1 Diabetes

• Dexcom G6 gives people with diabetes the power to manage their condition without fingersticks* or scanning

BURNABY, BC, April 16, 2021 /CNW/ - Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), is pleased to see that the governments of Saskatchewan and Manitoba both recognized in their budgets last week CGM for children and young adults living with diabetes.

On Tuesday, April 6^th, the Saskatchewan government announced they will cover the costs of CGM supplies for children and youth under 18 who are insulin dependent. While on Wednesday, April 7^th, the Manitoba government said it would start a new program to cover CGM systems for people in the province with type 1 diabetes up to age 25. Currently, only Yukon fully funds CGM for both children and adults living with type 1 diabetes.

"We are thrilled for the people and families in Saskatchewan and Manitoba who will be able to access this innovative technology that enables more effective diabetes management; however, individuals on intensive insulin therapies of all age groups would also benefit from CGM funding," said Laura Endres, Vice President and General Manager, Dexcom Canada. "We appreciate the opportunity to collaborate with Ministries of Health in both provinces as a result of Ministers Merriman and Stefanson's commitments to the type 1 diabetes community. Dexcom's objective is to ensure CGM technology, which can reduce the risk of costly long-term diabetes-related complications,¹ be funded regardless of the individual's age."

The Dexcom G6 CGM System uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a compatible smart device^† or receiver, giving those living with diabetes access to real-time glucose data as frequently as every five minutes. The Dexcom G6 also displays the direction and rate of glucose change, empowering users to make more informed decisions to proactively manage their glucose levels.

With a predictive Urgent Low Soon alert, the Dexcom G6 can warn the user in advance of severe hypoglycemia – allowing time to take appropriate action before it happens – day or night. Dexcom CGM is clinically proven to lower A1C, reduce hyper-and hypoglycemia, and increase time in range (i.e., the percentage of time a person's blood glucose levels spends within a target range).^2,3

The Dexcom G6 CGM System is the only sensor glucose monitoring system approved in Canada for children as young as two years old. More information on Dexcom G6 can be found at www.dexcom.com.

*If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

† For a list of compatible devices, visit www.dexcom.com/compatibility.

About Dexcom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.  

© 2021 Dexcom, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. All rights reserved.

References

________________________

¹ Roze S, Isitt J, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor Versus Self Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. Poster presentation presented at: 2020  Canadian Association for Population Therapeutics; October 27, 2020.

² Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the diamond randomized clinical trial. JAMA. 2017;317(4):371.

³ Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther. 2019;21(3):128-132.

SOURCE Dexcom, Inc.

Media Contact: Alena Atkinson, 705.206.9991, Veritas Communications, [email protected]